Download pg 1/2 PrZYTRAM XL® - NEW PRODUCT ANNOUNCEMENT TEVA

pg 1/2
January 10, 2007
TEVA NEUROSCIENCE IS PLEASED TO
ANNOUNCE THE INTRODUCTION OF AZILECT™
(rasagiline mesylate tablets).
PRODUCT QUANTITY
AZILECT™
0.5 mg
AZILECT™
1 mg
DIN
UPC
DESCRIPTION
30
tablets
white to off-white,
round, flat, beveled
tablets, debossed
02284642 068510012272 with "GIL" and "0.5"
below on one side
and plain on the
other
30
tablets
white to off-white,
round, flat, beveled
tablets, debossed
02284650 068510013279 with "GIL" and "1"
below on one side
and plain on the
other
PRICE
$210
$210
For further information concerning AZILECT™, please contact our medical
information services at 1-866-530-6065 or go to the website Azilect.ca for
a copy of the product monograph.
Teva has received feedback from several pharmacists using third party
information systems, that when AZILECT (rasagiline mesylate) a new
mono amine oxidase B inhibitor indicated for the treatment of the signs and
symptoms of idiopathic Parkinson’s disease as initial monotherapy and as
adjunct therapy to levodopa is prescribed with Comtan (Entacapone), a
category 1 warning is highlighted on the database. This is not correct, there
are no warnings regarding the use of AZILECT and Comtan together. In
addition there are no warnings or precautions against its use with
Dopamine Agonists.
AZILECT should not be used at daily doses exceeding the maximum
recommended (1mg/day) because of risks associated with nonselective
inhibition of MAO. There is no Tyramine dietary restriction required at this
maximum dose.
Pr
ZYTRAM XL® - NEW PRODUCT ANNOUNCEMENT
Purdue Pharma is pleased to announce the launch of Zytram XL
(controlled release tramadol hydrochloride tablets) - a new once-daily
treatment for pain of moderate severity in adults who require treatment for
several days or more.
STRENGTH
SIZE
DIN
UPC
PURDUE
LIST PRICE
PURDUE
ITEM CODE
150mg
50 tablets
02286424
060025801501
$80.00
80150
200mg
50 tablets
02286432
060025802003
$105.00
80200
300mg
50 tablets
02286440
060025803000
$152.50
80300
400mg
50 tablets
02286459
060025804007
$200.00
80400
Zytram XL is a schedule F product.
If you have any questions related to this announcement, please do not
hesitate to call Purdue Pharma Customer Service at 1-800-387-4501.
FAX:
1-800-420-3616
EMAIL:
[email protected]
INTRODUCING PRPRAVASA®:
ATTENTION QUEBEC PHARMACISTS
Paladin Labs Inc. is pleased to announce the introduction of PravASA®
(Acetylsalicylic acid delayed-release tablets USP and Pravastatin sodium
tablets). PravASA® is indicated in patients for whom treatment with both
pal-Pravastatin and Asaphen EC is appropriate.
PravASA® is available in 3 strengths.
STRENGTH
(PRAVASTATIN/
ASAPHEN EC)
PACKAGING
& SIZE
DIN
UPC
CODE
PRICE
PravASA®
10/81mg
30 tablets of
pal-Pravastatin and 30
tablets of Asaphen EC
02272415
628791003781
$28.59
PravASA®
20/81mg
30 tablets of
pal-Pravastatin and 30
tablets of Asaphen EC
02272423
628791003804
$33.72
PravASA®
40/81mg
30 tablets of
pal-Pravastatin and 30
tablets of Asaphen EC
02272431
628791003828
$40.62
PravASA® will be available for shipping as of January 2, 2007.
If you would like to place an order of PravASA®, please contact the
Paladin Customer Service at 1-866-340-1112.
Please refer to the Product Monograph for indications, contraindications,
warnings, precautions and dosing guidelines. Product Monograph is
available to health professionals on request.
Should you have any questions or require additional information
concerning the use of PravASA®, please contact our Medical
Information Centre at 1-888-550-6060.
VAPONEFRIN®
Sanofi-aventis Canada Inc. wishes to inform you that, effective
immediately, Vaponefrin® (racemic epinephrine HCl) is discontinued.
DIN
UPC
01927582
6 22337 81020 8
PRODUCT
Vaponefrin - 2.25% solution
for oral inhalation
FORMAT
30 mL
Should you have any questions regarding the above, including medical
information, please do not hesitate to call sanofi-aventis Customer
Service at 1-800-265-7927.
All PreScript Sample Vouchers have an incremental month automatically
added to the printed expiry dates to help patient compliance. A reminder
that the current Concerta® Sample Vouchers dated December 2006,
will be valid until the end of January 2007.
pg 2/2
January 10, 2007
NEW FORMULARY STATUS IN ONTARIO
Amgen Canada Inc. is pleased to announce that on January 2, 2007, the
government of Ontario added Aranesp® to the province's conditional list
of medicines covered by the Ontario Drug Benefit (ODB) formulary.
Effective immediately, physicians are no longer required to
complete Section 8 forms to obtain reimbursement approval from
the ODB.
For further information on Aranesp®, please contact your Amgen
Biopharmaceutical Sales Representative, or our Medical
Information Department at 1-866-50AMGEN or via e-mail at
[email protected]. Please refer to the Product
Monograph for complete prescribing and safety information.
Aranesp® is indicated for the treatment of anemia in patients with nonmyeloid malignancies, where anemia is
due to the effect of concomitantly administered chemotherapy.
Amgen Canada.
6755 Mississauga Road, Suite 400, Mississauga, ON L5N 7Y2
© 2007 Amgen Canada Inc. All rights reserved.
ATTENTION ONTARIO PHARMACISTS
Eprex is listed on the Ontario Drug Benefit Formulary
effective January 2, 2007
02231587
Eprex
10,000IU/mL
Pref Syr - 1mL Pk
JNO
142.5000
02206072
Eprex
20,000IU/mL
Inj Sol-1mL Vial Pk
JNO
267.9000
02240722
Eprex
40,000IU/mL
Pref Syr - 1mL Pk
JNO
401.8500
These products must be prescribed based on the following criteria:
For the treatment of chemotherapy-induced anemia in patients with
malignant cancer undergoing myelosuppressive chemotherapy with a
hemoglobin count of less than 100g/L and MCV level between 75fL and
120fL.
Note: Erythropoietin therapy should be re-assessed after 3 months of
therapy and should not be continued for those patients who do not
respond to therapy (i.e. Hgb level has not improved by at least 15g/L or
transfusions were required after first 2 weeks of therapy) or who are no
longer anemic.
The following dosage regimens for Eprex are recommended by the
Committee to Evaluate Drugs:
I. 150 IU/kg subcutaneously 3 times a week for 4 weeks. If no
response, the dose may be increased to 300 IU/kg subcutaneously
3 times a week; OR
II. 40,000 IU once weekly. If no response after 4 weeks, the dose may
be increased to 60,000 IU once weekly for 4 weeks.
ROCHE PATIENT ASSISTANCE
PROGRAM 1-888-748-8926
The Roche Patient Assistance Program will investigate reimbursement
options for patients who have been prescribed Roche Canada
rheumatoid arthritis, oncology and hematology therapies.
Reimbursement information for RITUXAN®, AVASTIN®, TARCEVA®,
XELODA® and HERCEPTIN® is now available on www.DrugCoverage.org.
This web site provides access to specific information on coverage through
private insurance, provincial / territorial and federal plans. It also provides
the appropriate reimbursement criteria, prior authorization / special
authorization request forms and instructions for submitting claims.
All trade-marks either owned or used under license by Hoffmann-La Roche Limited
®
Effective January 2, 2007 - PrFOSAVANCE®
(alendronate sodium/cholecalciferol [Vitamin D3])
Listed as a GENERAL BENEFIT on
The ONTARIO Drug benefit formulary
Merck Frosst Canada Ltd. is pleased to inform you that effective
January 2, 2007, FOSAVANCE®, the first and only therapy for the
treatment of osteoporosis which integrates alendronate sodium and
Vitamin D3 in a single once weekly tablet will be INCLUDED on
THE ONTARIO Drug Benefit Formulary as a GENERAL BENEFIT.
FOSAVANCE®: Based on the proven power of FOSAMAX® (alendronate
70 mg) PLUS vitamin D dosed weekly (cholecalciferol 2800 IU).
Choose FOSAVANCE® for your newly diagnosed osteoporosis patients.
Switch your patients taking FOSAMAX® (alendronate 70 mg) to
FOSAVANCE®.
FOSAVANCE® is a bone metabolism regulator containing alendronate
sodium, a bisphosphonate, and cholecalciferol (Vitamin D3), a secosterol.
FOSAVANCE® is indicated for the treatment of osteoporosis in
postmenopausal women and men. FOSAVANCE® increases bone mass
and can prevent fractures including those of the hip and spine (vertebral
compression fractures). The recommended dosage is one tablet once
weekly, containing 70 mg alendronate and 2800 IU Vitamin D3.
Like other bisphosphonate containing products, FOSAVANCE® may
cause local irritation of the upper gastrointestinal mucosa.
FOSAVANCE® is contraindicated for use in patients with abnormalities of
the esophagus which delay esophageal emptying such as stricture or
achalasia, inability to stand or sit upright for at least 30 minutes,
hypersensitivity to this drug or to any ingredient in the formulation,
hypocalcemia or renal insufficiency with creatinine clearance < 0.58 mL/s
(< 35 mL/min).
FOSAVANCE® alone should not be used to treat Vitamin D deficiency
(commonly defined as 25-hydroxyvitamin D < 22.5 nmol/L). Caution
should be exercised in patients with diseases associated with unregulated
overproduction of 1,25-dihydroxyvitamin D, as Vitamin D3
supplementation may worsen hypercalcemia and/or hypercalciuria in
these patients.
In a study of osteoporotic postmenopausal women and men, the safety
profile of FOSAVANCE® was similar to that of FOSAMAX® 70 mg once
weekly. In a clinical study, the most common drug-related adverse
experiences reported in ? 1% of patients taking FOSAMAX® 70 mg tablet
once weekly were abdominal pain (3.7%), musculoskeletal (bone,
muscle, joint) pain (2.9%), dyspepsia (2.7%), acid regurgitation (1.9%),
and nausea (1.9%).
Please consult the enclosed prescribing information for FOSAVANCE® for
information about indications, contraindications, warnings and precautions
with respect to upper gastrointestinal events, clinical adverse events, and
dosage and administration.
You may also visit our website at : www.merckfrosst.com
For additional information, please call the Customer Information Centre
at 1-800-567-2594.
® Registered Trademark of Merck & Co., Inc. Used under license.
11-07-FSD-06-CDN-34490202-L
Visit us at
www.ipharmadirect.com